New Sjögren's drug IBI355 enters human testing
NCT ID NCT06484855
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests an experimental drug called IBI355 in 30 adults with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. The main goal is to check the drug's safety and how the body processes it at different doses. Participants receive either IBI355 or a placebo by IV every 4 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI355 (an experimental drug given by IV infusion every 4 weeks)
What this could lead to
If successful, this could point toward a new treatment option to control Sjögren's syndrome symptoms and disease activity.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so it is primarily checking safety and dosing—not yet testing if the drug actually works. Many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230001, China